GlycoMimetics, Inc. (GLYC) SVP Helen M. Thackray Sells 2,000 Shares of Stock
GlycoMimetics, Inc. (NASDAQ:GLYC) SVP Helen M. Thackray sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $13.00, for a total value of $26,000.00. Following the sale, the senior vice president now owns 150,615 shares in the company, valued at approximately $1,957,995. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) opened at 13.97 on Tuesday. The company’s market cap is $457.14 million. The company has a 50-day moving average price of $11.34 and a 200-day moving average price of $9.14. GlycoMimetics, Inc. has a 1-year low of $3.82 and a 1-year high of $16.94.
GlycoMimetics (NASDAQ:GLYC) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.07. Equities research analysts expect that GlycoMimetics, Inc. will post ($1.22) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “GlycoMimetics, Inc. (GLYC) SVP Helen M. Thackray Sells 2,000 Shares of Stock” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/19/glycomimetics-inc-glyc-svp-helen-m-thackray-sells-2000-shares-of-stock.html.
A number of equities research analysts have recently issued reports on GLYC shares. ValuEngine upgraded GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research upgraded GlycoMimetics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, July 18th. Jefferies Group LLC dropped their price objective on GlycoMimetics from $16.00 to $9.00 and set a “buy” rating on the stock in a research note on Tuesday, June 6th. Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price objective on shares of GlycoMimetics in a research note on Tuesday, June 6th. Finally, Cowen and Company reiterated an “outperform” rating on shares of GlycoMimetics in a research note on Sunday, May 28th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. GlycoMimetics has a consensus rating of “Hold” and a consensus target price of $14.20.
Several large investors have recently made changes to their positions in the stock. Broadfin Capital LLC bought a new stake in GlycoMimetics during the second quarter worth $2,476,000. Dynamic Technology Lab Private Ltd bought a new stake in GlycoMimetics during the second quarter worth $146,000. Redmile Group LLC bought a new stake in GlycoMimetics during the second quarter worth $6,692,000. Janus Henderson Group PLC bought a new stake in GlycoMimetics during the second quarter worth $5,598,000. Finally, Goldman Sachs Group Inc. bought a new stake in GlycoMimetics during the second quarter worth $965,000. 92.63% of the stock is currently owned by institutional investors.
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Stock Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related stocks with our FREE daily email newsletter.